title: Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine.
abstract: The atypical antipsychotic drugs are considered a first-line treatment for mania in bipolar disorder with many having a proven superiority to the classical mood stabilisers. This review addresses the pharmacological mechanisms underlying this therapeutic efficacy, as well as those mechanisms considered responsible for the adverse effects of antipsychotic drugs, with a particular focus on the recently introduced asenapine. The high efficacy in bipolar mania of haloperidol, a relatively selective dopamine D2-like receptor antagonist, indicates that the one common receptor mechanism underlying antipsychotic effects on mania is antagonism at the D2 receptor. Serotonin receptors are implicated in antidepressant response, and relief of depressed mood in mixed states is likely to involve drug effects at one, or more likely several interacting, serotonin receptors. Asenapine shows a unique breadth of action at these sites, with potential effects at clinical doses at 5HT1A, 1B, 2A, 2C, 6 and 7 receptors. Antagonism at alpha2 adrenoceptors may also be involved. Adverse effects include those classically associated with dopamine D2 receptor blockade, the extrapyramidal side effects (EPS), and which are relatively diminished in the atypical (in comparison with the conventional) antipsychotics. A variety of protective mechanisms against EPS associated with different drugs include low D2 affinity, D2 partial agonism, high 5-HT2A and 2C antagonism. Similar effects at the D2 and 5-HT2C receptors may underlie the low propensity for hyperprolactinaemia of the atypicals, although the strong prolactin-elevating effect of risperidone reflects its relatively high blood/brain concentration ratio, a consequence of it being a substrate for the p-glycoprotein pump. Weight gain is a further concern of antipsychotic treatment of bipolar disorder which is particularly severe with olanzapine. Histamine H1, alpha1 adrenergic and particularly 5-HT2C receptors are implicated in this effect, although the lower propensity for weight gain shown by asenapine which, like olanzapine, binds to these receptors, indicates that other protective receptor mechanisms, or subtle differences in the 5-HT2C receptor-mediated effects, may be important. Of other peripheral and central effects, the pharmacological basis of sedation (H1 receptors) and postural hypotension (alpha1 adrenoceptors) are rather better understood. The relative benefits of atypical antipsychotics like asenapine can be understood from their receptor pharmacology, and this understanding is key to the future development of improved treatment for bipolar disorder.
authors: Biomedical Research Centre Sheffield Hallam University.
authors: Gavin P
authors: GP
authors: Reynolds
references: J Psychopharmacol. 2009 Jan;23(1):65-73
references: 18308814
references: Neuropsychopharmacology. 2001 Sep;25(3):410-22
references: 11522469
references: J Psychopharmacol. 2008 Jul;22(5):567-71
references: 18208914
references: Psychopharmacology (Berl). 2002 May;161(3):263-70
references: 12021829
references: Behav Brain Res. 1996;73(1-2):277-80
references: 8788518
references: Eur J Pharmacol. 2004 Nov 28;505(1-3):253-4
references: 15556160
references: J Psychopharmacol. 2006 Jul;20(4 Suppl):15-8
references: 16785265
references: Hum Psychopharmacol. 2005 Oct;20(7):493-500
references: 16118767
references: Drug Metab Pharmacokinet. 2005 Oct;20(5):368-78
references: 16272755
references: Eur Neuropsychopharmacol. 2009 Mar;19(3):177-87
references: 19116183
references: J Psychopharmacol. 2010 Mar;24(3):341-8
references: 18719049
references: J Clin Pharmacol. 2009 Nov;49(11):1297-308
references: 19843656
references: J Clin Psychopharmacol. 2001 Dec;21(6):575-82
references: 11763004
references: Psychosom Med. 1995 Sep-Oct;57(5):485-91
references: 8552740
references: Encephale. 2006 May-Jun;32(3 Pt 1):351-5
references: 16840929
references: Psychopharmacology (Berl). 2009 Nov;207(1):119-25
references: 19688201
references: Acta Psychiatr Scand Suppl. 2004;(420):55-64
references: 15128388
references: Pharmacol Ther. 2010 Jan;125(1):169-79
references: 19931306
references: Curr Drug Saf. 2010 Jan;5(1):97-104
references: 20210726
references: J Psychopharmacol. 2004 Sep;18(3):340-5
references: 15358977
references: Psychopharmacology (Berl). 2009 Oct;206(3):345-54
references: 19649616
references: J Clin Psychopharmacol. 2007 Oct;27(5):516-7
references: 17873689
references: Am J Psychiatry. 2003 Jan;160(1):13-23
references: 12505794
references: Schizophr Res. 2007 Jul;93(1-3):136-43
references: 17467954
references: Int J Neuropsychopharmacol. 2010 Apr;13(3):405-10
references: 19835670
references: Pharmacol Rep. 2010 Jul-Aug;62(4):564-77
references: 20884998
references: ScientificWorldJournal. 2010 Sep 14;10:1870-85
references: 20852829
references: Heart. 2003 Nov;89(11):1363-72
references: 14594906
references: Bipolar Disord. 2009 Jun;11 Suppl 2:45-54
references: 19538685
references: CNS Drugs. 2005;19 Suppl 1:1-93
references: 15998156
references: Lancet. 2011 Oct 8;378(9799):1306-15
references: 21851976
references: J Clin Psychiatry. 2005;66 Suppl 8:30-40
references: 16336034
references: Neuropsychopharmacology. 2003 Mar;28(3):519-26
references: 12629531
references: J Pharmacol Exp Ther. 2000 Oct;295(1):226-32
references: 10991983
references: Bipolar Disord. 2009 Dec;11(8):815-26
references: 19832806
references: Am J Psychiatry. 2009 Sep;166(9):980-91
references: 19687129
references: Int J Neuropsychopharmacol. 2010 May;13(4):541-8
references: 20047715
references: Neuropsychopharmacology. 2007 Jun;32(6):1209-15
references: 17077809
references: Behav Brain Res. 2011 Jun 1;219(2):273-9
references: 21262266
references: CNS Drugs. 2007;21(11):911-36
references: 17927296
references: BMC Psychiatry. 2011 Jun 20;11:101
references: 21689438
references: N Engl J Med. 2009 Jan 15;360(3):225-35
references: 19144938
references: Br J Psychiatry. 2009 Feb;194(2):101-3
references: 19182167
references: J Psychopharmacol. 2009 Jun;23(4):346-88
references: 19329543
references: Int J Clin Pract. 2009 Dec;63(12):1762-84
references: 19840150
references: Neuro Endocrinol Lett. 2008 Aug;29(4):435-7
references: 18766167
references: Drugs. 2004;64(20):2291-314
references: 15456328